Once and for all.
How can Neurolumen help my patients?
The Neurolumen is a non-invasive, drug-free unit that can be safely applied to any area of the body. When prescribed for your patients, they will receive fast-acting pain relief when needed — much like pain medication only minus the risk of adverse side effects. Patients who are referred to a Neurolumen provider will typically receive three 30-minute treatments a week for the first month, and then once a week or as needed after that.
Increase efficiency, patient care & income with one, easy to use device.
Purchase a Neurolumen device for your office and offer inpatient rehab treatments. The Physicians’ Clinic Package includes the Neurolumen PN-1000 plus additional wrap assemblies and electrode gel pads.
Having the Neurolumen on hand is a win-win for you and your patients.
With a typical treatment time at an average 30 minutes, physicians are able to schedule several patients per day, resulting in a rewarding opportunity.
Neurolumen helps fight ALL 3 Types of Pain.
Diabetic neuropathy, postherpetic neuralgia, spinal cord injury pain, phantom limb (post-amputation) pain, and post-stroke central pain.
Inflammatory bowel disease, appendicitis, rheumatoid arthritis, and herpes zoster.
Have your patients trained their bodies to live in pain?
Proven technology, trusted by the FDA.
The Neurolumen device has been certified by Intertek and received 510(k) clearance by the FDA in 2009. At that time a 10-patient trial was conducted for the purposes of demonstrating the unit’s effectiveness and safety. Each patient reported significant improvement following use of the Neurolumen.
Neurolumen has been safely and effectively used on hundreds of patients with amazing results. Currently, a 100-patient trial is underway that involves additional physicians in the community — this trial is designed to further establish the device.
80-year-old Male Patient
Severe uncontrolled Diabetes glucose levels average over 500.
Wound: No change after 2 months with previous treatment attempts.
No changes in therapy other than the addition of Neurolumen Aug 28.